Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Zizhao Qi"'
Autor:
Jia Liao, Miaohan Qiu, Xiaolin Su, Zizhao Qi, Ying Xu, Haiwei Liu, Kai Xu, Xiaozeng Wang, Jing Li, Yi Li, Yaling Han
Publikováno v:
Lipids in Health and Disease, Vol 23, Iss 1, Pp 1-12 (2024)
Abstract Background Residual risk assessment for acute coronary syndrome (ACS) patients after sufficient medical management remains challenging. The usefulness of measuring high-sensitivity C-reactive protein (hsCRP) and remnant cholesterol (RC) in a
Externí odkaz:
https://doaj.org/article/362b0c0ca01446df9d36fad26612def7
Autor:
Jing Li, Sanbao Chen, Sicong Ma, Mingque Yang, Zizhao Qi, Kun Na, Miaohan Qiu, Yi Li, Yaling Han
Publikováno v:
Cardiovascular Therapeutics, Vol 2022 (2022)
Introduction. Optimal anticoagulants for patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI) are unclear. This retrospective observational study is aimed at evaluating efficacy and safety of bivalirudin versus unf
Externí odkaz:
https://doaj.org/article/4dd8c726ce3a4a00a2a95f3e40bd7986
Autor:
Miaohan Qiu, Yi Li, Kun Na, Zizhao Qi, Sicong Ma, He Zhou, Xiaoming Xu, Jing Li, Kai Xu, Xiaozeng Wang, Yaling Han
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2022)
Backgrounds: A plug-and-play standardized algorithm to identify the ischemic risk in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) could play a valuable step to help a wide spectrum of clinic workers.
Externí odkaz:
https://doaj.org/article/2fc985c7742b4f3f86f0b28cf28defcb
Autor:
Xin Zhao, Sicong Ma, Yi Kang, Chengchun Tang, Bin Liu, Hong Jiang, Mingqi Zheng, Yu Tang, Hongbin Sun, Yongqiang Liu, Xiaojuan Lai, Yanchun Gong, Yongguo Li, Zizhao Qi, Ling Ren, Jing Li, Yi Li, Yaling Han
Publikováno v:
European Heart Journal - Cardiovascular Pharmacotherapy. 8:806-814
Aims Vicagrel, a novel antiplatelet prodrug to overcome the residual high platelet reactivity of clopidogrel induced by inactive metabolism and cytochrome P450 (CYP) 2C19 polymorphisms, provides favourable antiplatelet inhibition in healthy volunteer
Publikováno v:
Catheterization and Cardiovascular Interventions. 99:1448-1455
To assess the effectiveness and safety of bivalirudin compared with heparin monotherapy in elderly patients undergoing percutaneous coronary intervention (PCI).Bivalirudin is recommended for periprocedural use in patients undergoing PCI who are of hi
Autor:
Zaixin Jiang, Yi Li, Chenghui Yan, Xiaolin Zhang, Quanyu Zhang, Jing Li, Xiaoxiang Tian, Miaohan Qiu, Zhenyang Liang, Sichong Ma, Kun Na, Ziqi Li, Sanbao Chen, Yu Zhao, Zizhao Qi, Xiying Liu, Yaling Han
Publikováno v:
Clinical research in cardiology : official journal of the German Cardiac Society.
To investigate the frequency of clonal hematopoiesis of indeterminate potential (CHIP) and evaluate its impacts on outcomes in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) in the absence of tradition
Autor:
Sanbao Chen, Jing Li, Miaohan Qiu, Sicong Ma, Zaixin Jiang, Kun Na, Zizhao Qi, Yuzhuo Li, Yi Li, Yaling Han
Publikováno v:
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventionsREFERENCES. 99
This study evaluated clinical outcomes of switching from clopidogrel to ticagrelor in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). The clinical benefit of in-hospital switching from clopidogrel to t
Autor:
Yuzhuo Li, Jing Li, Miaohan Qiu, Sicong Ma, Kun Na, Xiaoying Li, Zizhao Qi, Sanbao Chen, Yi Li, Yaling Han
Publikováno v:
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventionsREFERENCES. 99
To evaluate the effectiveness and safety of ticagrelor versus clopidogrel in patients with acute coronary syndromes (ACS) undergoing complex percutaneous coronary intervention (PCI).It remains inconclusive whether ticagrelor is superior to clopidogre
Publikováno v:
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventionsREFERENCES. 95
OBJECTIVES To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months in acute coronary syndrome (ACS) patients with intermediate-risk to high-risk of developing ischemia according to the Global Acute Coronary Event Registra
Publikováno v:
Catheterization & Cardiovascular Interventions; 2020 Supplement, Vol. 95, p665-673, 9p